ProQR gibt positive Zwischenergebnisse aus der klinischen Phase-I/II-Studie zu QR-110 bei Patienten mit LCA10 bekannt und plant den Beginn einer Phase-II/III-Zulassungsstudie
September 05, 2018 05:46 ET
|
ProQR Therapeutics N.V.
QR-110 zeigte gemessen an Sehschärfe und Umfang der Mobilität eine schnelle und anhaltende Verbesserung des Sehvermögens bei der Mehrheit der Patienten QR-110 war gut verträglich, ohne schwerwiegende...
ProQR annonce des résultats intermédiaires positifs pour un essai clinique de phase 1/2 du QR-110 chez des patients souffrant de ACL10 et prévoit de commencer un essai pivot de phase 2/3
September 05, 2018 05:46 ET
|
ProQR Therapeutics N.V.
Le QR-110 a permis une amélioration rapide et soutenue de la vision chez la majorité des sujets, tant en termes d’acuité visuelle que de mobilité Le QR-110 a été bien toléré sans événements...
ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial
September 05, 2018 04:00 ET
|
ProQR Therapeutics N.V.
QR-110 demonstrated rapid and sustained improvement in vision in the majority of subjects, as measured by visual acuity and mobility course QR-110 was well-tolerated with no serious adverse events A...
ProQR to Present Interim Phase 1/2 Results for QR-110 in Leber’s Congenital Amaurosis 10 at the Symposium for Retinal Degeneration on Sept. 5th
August 15, 2018 07:00 ET
|
ProQR Therapeutics N.V.
Presentation at the 18th International Symposium on Retinal Degeneration (RD2018) at 8:30 am GMT on Sept. 5th Investor conference call to be held at 8:15 am ET on Sept. 5th LEIDEN,...
ProQR Announces Publication on QR-110 for Leber’s Congenital Amaurosis 10 in the Journal Molecular Therapy - Nucleic Acids
August 01, 2018 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Aug. 01, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
ProQR Announces Presentations on Programs in Ophthalmology at Conferences in July
July 12, 2018 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, July 12, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines...
ProQR Provides Enrollment Update on QR-110 Clinical Trial and Highlights Ophthalmology Presentations at ARVO
April 23, 2018 07:00 ET
|
ProQR Therapeutics N.V.
Key Updates Enrollment is on track in the ongoing Phase 1/2 clinical trial of QR-110 with eight out of twelve patients with LCA 10 enrolled.The trial is on track to announce interim six-month data on...
ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness
November 13, 2017 07:00 ET
|
ProQR Therapeutics N.V.
Key Updates The first patient has received the first dose of QR-110 in the Phase 1/2 safety & efficacy clinical trial (PQ-110-001: NCT03140969) in children and adults with Leber’s congenital...
ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10
May 31, 2017 07:00 ET
|
ProQR Therapeutics N.V.
Key Updates ProQR receives Fast Track designation by the U.S. Food and Drug Administration (FDA). Closer interaction with FDA could potentially accelerate the development of QR-110 in patients...
ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome
May 01, 2017 07:00 ET
|
ProQR Therapeutics
Key updates At ARVO ProQR will present additional positive pre-clinical proof-of-concept (PoC) data for QR-110 targeting LCA 10. The company has recently received IND clearance to start clinical...